INSPECS Group (SPEC) Fair Value & Analysis
Healthcare · GB · Market cap 85.9M GBX
Fair value as of: Jun 25, 2026
From 9 valuation models · updated 4 days ago
Fair value updated Jun 25, 2026 — revised from £1.98 to £0.5200 (−73.7%) since Jun 24, 2026. Share price +14.8% over the past month.
Price vs Fair Value (12 months)
12‑month range £0.3950 – £1.01 · fair‑value band £0.2800 – £0.7600 · the £0.9700 price screens above the £0.5200 fair value. As of Jun 25, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
INSPECS Group (SPEC) currently trades at £0.9700, while our model-based Fair Value estimate is £0.5200 — implying the stock looks roughly 46.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, INSPECS Group generated revenue of £195M at a net margin of -4.2%. Revenue declined 3.0% year over year. It earns a return on equity of -4.9%. Net debt stands at £43.8M. Fundamentals as of Jun 25, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 25, 2026. TTM = trailing twelve months.
About the company
INSPECS Group plc designs, produces, sells, markets, and distributes fashion eyewear, lenses, and OEM products in the United Kingdom, Europe, North America, South America, Asia, Africa, and Australia. It operates through Frames and Optics product distribution and Manufacturing segments. The company offers its products under the retail brands, such as Barbour, Barbour International, BUFFALO David Bitton, CAT, Free Country, Henri-Lloyd, Hype, JOSEPH, Lamb, Liberty, Lyle & Scott, Marc O'Polo, MINI, O'Neill, RADLEY, Superdry & Co, TALBOT RUNHOF, Ted Baker, and VIKTOR & ROLF and in house brands under BOTANIQ, SAVILE ROW Titanium, SAVILE ROW, BRENDEL Eyewear, FREIGEIST, HUMPHREY'S eyewear, JOS ESCHENBACH, and TITANFLEX names. INSPECS Group plc was founded in 1988 and is based in Bath, United Kingdom.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
INSPECS Group reported revenue of £192M in FY2025 versus £183M in FY2021, a compound +1.2%/yr. Reported net income was −£6.5M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jun 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $422.06 | $165.35 | -61% |
| EssilorLuxottica Société anonyme ESLOF | $205.86 | $114.90 | -44% |
| HOYA Corporation HOCPY | $162.33 | $101.00 | -38% |
| Medline Inc MDLN | $35.30 | $30.15 | -15% |
| Becton, Dickinson and Company BDX | $147.79 | $124.26 | -16% |
| Alcon Inc ALC | $65.18 | $44.21 | -32% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is INSPECS Group (SPEC) undervalued?
What is the fair value of SPEC?
What is the quality score of SPEC?
What is the revenue of INSPECS Group (SPEC)?
What is the net profit margin of SPEC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.